GlassScriptPhysician profile
Kenneth P Metoyer
NPI 1265692156
$2,275.87
in general payments reported to CMS, 2019-2025
25 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $146 · 2021: $294 · 2022: $448 · 2023: $338 · 2024: $377 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $438.43 | 2022-2024 | |
| Abbvie INC. | $320.88 | 2019-2025 | |
| Lilly USA, LLC | $279.39 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $178.25 | 2019-2021 | |
| Novo Nordisk INC | $161.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $120.94 | 2019-2021 | |
| Amgen INC. | $83.64 | 2019-2024 | Repatha |
| Glaxosmithkline, LLC. | $81.80 | 2019-2025 | Shingrix |
| Pfizer INC. | $77.42 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $61.24 | 2019-2022 | |
| Nevro Corp. | $60.31 | 2022-2023 | Senza |
| Merck Sharp & Dohme LLC | $51.32 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sandoz INC. | $41.42 | 2024 | Hyrimoz |
| Organon LLC | $37.82 | 2024-2025 | Hadlima, Renflexis |
| Janssen Biotech, INC. | $35.32 | 2023-2024 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.75 | 2022-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $33.34 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $33.16 | 2024 | Veozah |
| Horizon Therapeutics Plc | $33.02 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $27.13 | 2025 | Gemtesa |
| Organogenesis INC. | $21.32 | 2021 | |
| Aurinia Pharma U.S., INC. | $18.79 | 2024 | Lupkynis |
| Kowa Pharmaceuticals America, INC. | $16.22 | 2023 | Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2022 | |
| Eisai INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Metoyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.